Click Here For COVID-19 (Coronavirus) Studies

RecruitMe Clinical Trial

WATCHMAN FLX versus NOAC for EMbolic ProtectION in the Management of Patients with Non-Valvular Atrial Fibrillation
Champion Atrial Fibrillation (AF)
Sponsor:Boston Scientific Corporation
Enrolling:Male and Female Patients
Clinic Visits:9
Minimum Age:18 years old
IRB Number:AAAT2212
U.S. Government ID:NCT04394546
Contact: Cathy Moore: 347-514-3366 / cjm2285@cumc.columbia.edu
Additional Study Information:

This is a prospective, randomized, multi-center global investigational study. The primary objective is to determine if left atrial appendage closure with the WATCHMAN FLX device is a reasonable alternative to non-vitamin K oral anticoagulants (NOACs - drugs that inhibits clotting) in patients with Atrial Fibrillation (AF) - irregular heart rhythm caused by other things, such as high blood pressure or an overactive thyroid gland.

Do You Qualify?
Do you have atrial fibrillation (AF)?YesNo
Are you on anticoagulation for reasons other than AF-related stroke risk reduction?YesNo
Have you had a transient ischemic attack (TIA) or Stroke?YesNo
Have you had a patent foramen ovale (PFO)/ atrial septal defect (ASD) closed?YesNo
Submit
Cancel
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Cathy Moore
Email: cjm2285@cumc.columbia.edu
Phone: 347-514-3366